Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab
AIM: To determine the time course of changes in the blood levels of antibodies (Ab) to complement component C1q (a-C1q) in patients with systemic lupus erythematosus (SLE) during rituximab (RTM) therapy and the association with organ injuries in SLE/MATERIAL AND METHODS: The study involved 41 patien...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2013-05-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31281 |
| _version_ | 1818308475627765760 |
|---|---|
| author | M É Tsanian A V Torgashina E N Aleksandrova S K Solov'ev E L Nasonov |
| author_facet | M É Tsanian A V Torgashina E N Aleksandrova S K Solov'ev E L Nasonov |
| author_sort | M É Tsanian |
| collection | DOAJ |
| description | AIM: To determine the time course of changes in the blood levels of antibodies (Ab) to complement component C1q (a-C1q) in patients with systemic lupus erythematosus (SLE) during rituximab (RTM) therapy and the association with organ injuries in SLE/MATERIAL AND METHODS: The study involved 41 patients (3 men and 38 women; their median age was 27.5 (range 22-36) years) with definite SLE. Their blood a-C1q levels were determined by enzyme immunoassay. The levels and detection rates of a-C1q were estimated in relation to organ injuries, the time course of RTM therapy-induced changes in a-C1q levels were determined. High-positive (>30 U/ml), low-positive (10-30 U/ml), and negative (≤10 U/ml) a-C1q levels were found/RESULTS: A-C1q was detected in 19 (46.3%) patients with different clinical manifestations of SLE. The patients with renal diseases had high-positive levels of a-C1q statistically significantly more frequently than those without renal involvement (p=0.04). Low-positive and negative a-C1q levels were found in 15 of 16 without nephritis. There was a statistically significant positive correlation of the concentration of a-Clq with Ab to double-stranded DNA (a-dsDNA), Ab to nucleosomes, the SLE Disease Activity Index 2000 (SLEDAI-2K), erythrocyturia, hematuria and a negative correlation between a-C1q and complement components C3 and C4. Just after one month of RTM therapy, the patients with nephritis were observed to have a statistically significant decrease in the levels of a-C1q (p=0.002), which persisted 1 year after the treatment (p=0.006). Nineteen patients with the higher baseline concentrations of a-C1q after RTM treatment showed a statistically significant decrease in the levels of a-C1q at 1-, 3-, 6-, and 12-month follow-up (p=0.016, 0.02, 0.035, and 0.04, respectively) which was accompanied by the decreased SLEDAI-2K (p |
| first_indexed | 2024-12-13T07:14:52Z |
| format | Article |
| id | doaj.art-e853f9ae7d014e03bc8e81480ca592b8 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-13T07:14:52Z |
| publishDate | 2013-05-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-e853f9ae7d014e03bc8e81480ca592b82022-12-21T23:55:35Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422013-05-01855535928297Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximabM É TsanianA V TorgashinaE N AleksandrovaS K Solov'evE L NasonovAIM: To determine the time course of changes in the blood levels of antibodies (Ab) to complement component C1q (a-C1q) in patients with systemic lupus erythematosus (SLE) during rituximab (RTM) therapy and the association with organ injuries in SLE/MATERIAL AND METHODS: The study involved 41 patients (3 men and 38 women; their median age was 27.5 (range 22-36) years) with definite SLE. Their blood a-C1q levels were determined by enzyme immunoassay. The levels and detection rates of a-C1q were estimated in relation to organ injuries, the time course of RTM therapy-induced changes in a-C1q levels were determined. High-positive (>30 U/ml), low-positive (10-30 U/ml), and negative (≤10 U/ml) a-C1q levels were found/RESULTS: A-C1q was detected in 19 (46.3%) patients with different clinical manifestations of SLE. The patients with renal diseases had high-positive levels of a-C1q statistically significantly more frequently than those without renal involvement (p=0.04). Low-positive and negative a-C1q levels were found in 15 of 16 without nephritis. There was a statistically significant positive correlation of the concentration of a-Clq with Ab to double-stranded DNA (a-dsDNA), Ab to nucleosomes, the SLE Disease Activity Index 2000 (SLEDAI-2K), erythrocyturia, hematuria and a negative correlation between a-C1q and complement components C3 and C4. Just after one month of RTM therapy, the patients with nephritis were observed to have a statistically significant decrease in the levels of a-C1q (p=0.002), which persisted 1 year after the treatment (p=0.006). Nineteen patients with the higher baseline concentrations of a-C1q after RTM treatment showed a statistically significant decrease in the levels of a-C1q at 1-, 3-, 6-, and 12-month follow-up (p=0.016, 0.02, 0.035, and 0.04, respectively) which was accompanied by the decreased SLEDAI-2K (phttps://ter-arkhiv.ru/0040-3660/article/view/31281systemic lupus erythematosusa-c1qlupus nephritisrituximab |
| spellingShingle | M É Tsanian A V Torgashina E N Aleksandrova S K Solov'ev E L Nasonov Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab Терапевтический архив systemic lupus erythematosus a-c1q lupus nephritis rituximab |
| title | Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| title_full | Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| title_fullStr | Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| title_full_unstemmed | Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| title_short | Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| title_sort | anti c1q antibodies in patients with systemic lupus erythematosus treated by rituximab |
| topic | systemic lupus erythematosus a-c1q lupus nephritis rituximab |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31281 |
| work_keys_str_mv | AT metsanian antic1qantibodiesinpatientswithsystemiclupuserythematosustreatedbyrituximab AT avtorgashina antic1qantibodiesinpatientswithsystemiclupuserythematosustreatedbyrituximab AT enaleksandrova antic1qantibodiesinpatientswithsystemiclupuserythematosustreatedbyrituximab AT sksolovev antic1qantibodiesinpatientswithsystemiclupuserythematosustreatedbyrituximab AT elnasonov antic1qantibodiesinpatientswithsystemiclupuserythematosustreatedbyrituximab |